Company profile
Alkermes plc.
NASDAQ:ALKSBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Meloxicam | approved | — | 3 | approved |
| ARIPIPRAZOLE LAUROXIL | phase3 | — | 4 | no active trials |
| METHYLSAMIDORPHAN CHLORIDE | phase2 | — | 3 | no active trials |
| Samidorphan | phase2 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (78)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03963973 | phase1 | terminated | 2019-05-16 | 2020-01-22 | Alkermes, Inc. | A 28 Day Parallel Group Study to Assess the Effects of RDN-929 |
| NCT02272764 | phase1 | completed | 2014-10-01 | 2014-11-01 | Alkermes, Inc. | A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers |
| NCT02545439 | phase1 | completed | 2015-07-01 | 2015-10-01 | Alkermes, Inc. | A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers |
| NCT03610048 | phase3 | terminated | 2018-08-09 | 2020-05-01 | Alkermes, Inc. | A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) |
| NCT02141399 | phase3 | completed | 2014-05-01 | 2017-11-20 | Alkermes, Inc. | A Long-Term Safety Study of ALKS 5461 |
FDA applications (0)
No records yet.